ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.64
0.08%
US Tech 100
18,079.20
-0.20%
S&P 500
5,297.10
-0.21%
US Dollar vs CAD
1.36234
0.06%
Bitcoin
65,990.52
1.15%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ENDRA Life Sciences Inc (NDRA)

  7. ENDRA Life Sciences Inc (NDRA) News

NDRA

ENDRA Life Sciences (NDRA)

ENDRA Life Sciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NDRA
DateTimeSourceHeadlineSymbolCompany
05/14/20243:26PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NDRAENDRA Life Sciences Inc
05/14/20243:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
05/14/20243:05PMBusiness WireENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
05/10/20244:18PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
05/10/20244:17PMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:NDRAENDRA Life Sciences Inc
05/07/20247:00AMBusiness WireENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024NASDAQ:NDRAENDRA Life Sciences Inc
05/02/20247:00AMBusiness WireENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International PatentsNASDAQ:NDRAENDRA Life Sciences Inc
03/28/20243:05PMBusiness WireENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
03/21/20247:00AMBusiness WireENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024NASDAQ:NDRAENDRA Life Sciences Inc
02/27/20247:00AMBusiness WireENDRA Life Sciences Installs First TAEUS System in the UKNASDAQ:NDRAENDRA Life Sciences Inc
02/23/20244:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NDRAENDRA Life Sciences Inc
02/21/20247:00AMBusiness WireNew ICD-10-CM Code by the World Health Organization Paves the Way for Improved NAFLD Diagnostics Including ENDRA Life Sciences’ TAEUS SystemNASDAQ:NDRAENDRA Life Sciences Inc
02/14/20247:30AMBusiness WireENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and EuropeNASDAQ:NDRAENDRA Life Sciences Inc
12/29/20234:07PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NDRAENDRA Life Sciences Inc
11/29/20237:00AMBusiness WireENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System TechnologyNASDAQ:NDRAENDRA Life Sciences Inc
11/27/20237:00AMBusiness WireENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor ConferenceNASDAQ:NDRAENDRA Life Sciences Inc
11/14/20233:05PMBusiness WireENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
11/14/20233:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
11/08/20237:00AMBusiness WireENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New PatentsNASDAQ:NDRAENDRA Life Sciences Inc
11/07/20233:05PMBusiness WireENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023NASDAQ:NDRAENDRA Life Sciences Inc
11/06/20237:00AMBusiness WireENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023NASDAQ:NDRAENDRA Life Sciences Inc
09/07/20237:00AMBusiness WireAbstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023NASDAQ:NDRAENDRA Life Sciences Inc
08/30/20237:00AMBusiness WireENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDANASDAQ:NDRAENDRA Life Sciences Inc
08/23/20237:00AMBusiness WireENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European PatentsNASDAQ:NDRAENDRA Life Sciences Inc
08/14/20233:53PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NDRAENDRA Life Sciences Inc
08/14/20233:45PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NDRAENDRA Life Sciences Inc
08/14/20233:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
08/14/20233:05PMBusiness WireENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:NDRAENDRA Life Sciences Inc
08/14/202312:30PMBusiness WireENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDANASDAQ:NDRAENDRA Life Sciences Inc
08/10/20237:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NDRAENDRA Life Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:NDRA

Your Recent History

GATE
SKLUSDT
SKALE
NASDAQ
FGMCU
FG Merger
KUCN
PSLUSDT
Pastel
BIT
UB7HN4
Unicredit Bank
AMEX
NQH
Str PD Ndq Tier 4/06
BIT
UV4LLS
UniCredit Bank
LSE
MIGO
Migo Opportunities
COIN
MNTISBTC
NASDAQ
VERO
Venus Concept
KOSPI
550068
QV Kosdaq 150 ETN 68
NASDAQ
JOUT
Johnson Outdoors
BIT
I07245
INTESA SANPAOLO
BIT
I06012
Banca Imi
LSE
57CD
Cred Ag Co 24
AQSE
COFF.GB
WisdomTree Commodity Sec...
NYSE
RWT
Redwood
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved